BCLI Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own BCLI shares is 44, representing 13.9% of the company's common stock.

SUSQUEHANNA INTERNATIONAL GROUP, LLP, in the last quarter, reduced its stake in BCLI by -100% restricting it's holding to 0 shares of worth nearly -. CITADEL ADVISORS LLC also lessened -69.23% of the BCLI shares from its portfolio, reducing its holding to 800 shares of worth $452.00. BANK OF AMERICA CORP /DE/ also shunned BCLI shares holding by -5.12% last quarter which brought its holding to 1 thousand shares worth $564.00.

As per its latest 13F filing, JPMORGAN CHASE & CO increased its stake in BCLI by 49.3% in the last quarter. The institutional holder raised its holding to 106 shares having worth more than $60.00. CRANBROOK WEALTH MANAGEMENT, LLC also added 100% more shares of BCLI to its portfolio, raising its holding to 1 thousand shares of worth $565.00. CLEARSTEAD ADVISORS, LLC also increased its BCLI shares holding by 100% which brought its holding to 1.5 thousand shares worth $822.00.

The insider with the most stakes in BCLI is Abbhi Sankesh , director at the company. Additionally, BCLI stock is highly held by Co-Chief Executive Officer Lindborg Stacy and director ARBEL IRIT among others.

Company executives, directors, and other insiders own 9.04% percent of Brainstorm Cell Therapeutics Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which BCLI insiders have sold stock, totaling 0 shares. Insiders that have sold shares include DAGHER IBRAHIM B., ACC INTERNATIONAL HOLDINGS LTD., and ARBEL IRIT.

There have been 2 transaction(s) during the past 6-months in which Brainstorm Cell Therapeutics Inc. insiders have bought stock, totalling 23836 shares

Around 1.27M Brainstorm Cell Therapeutics Inc. shares are held by insiders, which represents about 9.04% of BCLI stock.

BCLI director, Abbhi Sankesh holds the largest portfolio of the company's shares. BCLI shares owned by Abbhi total nearly 2.16 million.

SUSQUEHANNA INTERNATIONAL GROUP, LLP is the largest institutional owner in BCLI which holds 0 shares worth - or 0% of the total BCLI shares outstanding followed by JPMORGAN CHASE & CO with ownership of 106 shares representing 0% of the BCLI ownership. WESTSIDE INVESTMENT MANAGEMENT, INC. is the third largest stakeholder with 200 shares or 0% of the ownership worth more than $112.00.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the BCLI is concerned, it is a stock which is not optionable.

Number of BCLI shares short is 109.80K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 5.70M shares of BCLI are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, BCLI has 4.27M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for BCLI is 1.25.